ResMed Inc (RMD)vsJIN MEDICAL INTERNATIONAL LTD. Ordinary Shares (ZJYL)
RMD
ResMed Inc
$226.31
-0.82%
HEALTHCARE · Cap: $33.31B
ZJYL
JIN MEDICAL INTERNATIONAL LTD. Ordinary Shares
$1.94
-3.96%
HEALTHCARE · Cap: $303.70M
Smart Verdict
WallStSmart Research — data-driven comparison
ResMed Inc generates 25994% more annual revenue ($5.40B vs $20.69M). RMD leads profitability with a 27.5% profit margin vs 5.8%. RMD trades at a lower P/E of 22.6x. RMD earns a higher WallStSmart Score of 70/100 (B).
RMD
Strong Buy70
out of 100
Grade: B
ZJYL
Avoid27
out of 100
Grade: F
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
+14.4%
Fair Value
$303.30
Current Price
$226.31
$76.99 discount
Margin of Safety
-127.0%
Fair Value
$0.07
Current Price
$1.94
$1.87 premium
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Strong operational efficiency at 35.2%
Safe zone — low bankruptcy risk
Every $100 of equity generates 26 in profit
Keeps 28 of every $100 in revenue as profit
Reasonable price relative to book value
Areas to Watch
No major concerns identified
Smaller company, higher risk/reward
ROE of 4.8% — below average capital efficiency
5.8% margin — thin
Premium valuation, high expectations priced in
Comparative Analysis Report
WallStSmart ResearchBull Case : RMD
The strongest argument for RMD centers on Operating Margin, Altman Z-Score, Return on Equity. Profitability is solid with margins at 27.5% and operating margin at 35.2%. Revenue growth of 11.0% demonstrates continued momentum.
Bull Case : ZJYL
The strongest argument for ZJYL centers on Price/Book.
Bear Case : RMD
No major red flags identified for RMD, but monitor valuation.
Bear Case : ZJYL
The primary concerns for ZJYL are Market Cap, Return on Equity, Profit Margin. A P/E of 194.0x leaves little room for execution misses.
Key Dynamics to Monitor
RMD profiles as a mature stock while ZJYL is a value play — different risk/reward profiles.
ZJYL carries more volatility with a beta of 9.47 — expect wider price swings.
RMD is growing revenue faster at 11.0% — sustainability is the question.
RMD generates stronger free cash flow (311M), providing more financial flexibility.
Bottom Line
RMD scores higher overall (70/100 vs 27/100), backed by strong 27.5% margins and 11.0% revenue growth. Both earn "Strong Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
ResMed Inc
HEALTHCARE · MEDICAL INSTRUMENTS & SUPPLIES · USA
ResMed is a San Diego, California-based medical equipment company. It primarily provides cloud-connectable medical devices for the treatment of sleep apnea (such as CPAP devices and masks), chronic obstructive pulmonary disease (COPD), and other respiratory conditions.
Visit Website →JIN MEDICAL INTERNATIONAL LTD. Ordinary Shares
HEALTHCARE · MEDICAL INSTRUMENTS & SUPPLIES · USA
Jin Medical International Ltd. designs and manufactures wheelchairs and living aids products.
Compare with Other MEDICAL INSTRUMENTS & SUPPLIES Stocks
Want to dig deeper into these stocks?